Bernard Coulie (file photo)
With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.